A randomized, double-blind, vehicle-controlled crossover study to determine the anti-pruritic efficacy, safety and local dermal tolerability of a topical formulation (SRD174 cream) of the long-acting opiod antagonist nalmefene in subjects with atopic dermatitis

Journal of Drugs in Dermatology

Volumn 10, Issue 8, 2011, Pages 853-860

  Herzog, Jo Lynne ^a   Solomon, James A ^b   Draelos, Zoe ^c   Fleischer Jr , Alan ^d   Stough, Dow ^e   Wolf, David I ^f   Abramovits, William ^g   Werschler, William ^h   Green, Emma ⁱ   Duffy, Maeve ⁱ   Rothaul, Alan ⁱ   Tansley, Robert ⁱ  

^a RADIANT RESEARCH   (United States)

^b Advanced Dermatology and Cosmetic Surgery   (United States)

^c DERMATOLOGY CONSULTING SERVICES   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e Burke Pharmaceutical Research   (United States)

^f Dermatology Specialists Inc   (United States)

^g BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^h Premier Clinical Research   (United States)

ⁱ Serentis Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NALMEFENE;

ADULT; ARTICLE; ATOPIC DERMATITIS; BODY SURFACE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ERYTHEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SKIN PRURITUS; VISUAL ANALOG SCALE;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, TOPICAL; ADULT; ANTIPRURITICS; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; DRUG EVALUATION; ELECTRONIC HEALTH RECORDS; EMOLLIENTS; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; PRURITUS; RECEPTORS, OPIOID; TREATMENT OUTCOME;

EID: 80053073997     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Kjellberg F, Tramér MR. Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials. Eur J Anaesthesiol. 2001;18(6):346-357. (Pubitemid 34603784)
2. Bergasa NV, Alling DW, Talbot TL, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis: A double-blind, randomized, controlled trial. Ann Intern Med. 1995; 123(1):161-167.
3. Metze D, Reimann S, Beissert S, et al. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol. 1999;41(4):533-539. (Pubitemid 29480399)
4. Wolfhagen FH, Sternieri E, Hop WC, et al. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997;113(4):1264-1269. (Pubitemid 27418980)
5. Terg R, Coronel E, Sordá J, et al. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol. 2002;37(6):717-722. (Pubitemid 35404208)
6. Pauli-Magnus C, Mikus G, Alscher DM, et al. Naltrexone does not relieve uremic pruritus: Results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol. 2000;11(3):514-519. (Pubitemid 30115081)
7. Peer G, Kivity S, Agami O, et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 1996; 348(9041):1552-1554.
8. Legroux-Crespel E, Cledès V, Misery L, et al. A Comparative study on the effects of naltrexone and loratadine on uremic pruritus. Dermatology. 2004; 208(4):326-330. (Pubitemid 38736654)
9. Monroe EW. Efficacy and Safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis. J Am Acad Dermatol 1989;21(1):135-136. (Pubitemid 19171479)
10. Bergasa NV, Schmitt JM, Talbot TL, et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998;27(3):679-684. (Pubitemid 28103542)
11. Jones EA, Dekker LR. Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis. Gastroenterology 2000;118(2):431-432.
12. Stein C. The control of peripheral tissue by opioids. N Engl J Med 1995;332(25):1685-1690.
13. Bigliardi-Qi M, Sumanovski LT, Bücher S, et al. Mu-opiate receptor and beta-endorphin expression in nerve endings and keratinocytes in human skin. Dermatology 2004; 209(3): 183-189. (Pubitemid 39370325)
14. Bigliardi-Qi M, Lipp B, Sumanouski LT, et al. Changes of epidermal mu-opiate receptor expression and nerve endings in chronic atopic dermatitis. Dermatology 2005; 210(2):91-99. (Pubitemid 40463197)
15. Lee CH, Chuang HY, Shih CC, et al. Transepidermal water loss, serum IgE and beta-endorphin as important and independent biological markers for development of itch intensity in atopic dermatitis. Br J Dermatol 2006;154(6):1100-1107. (Pubitemid 43727391)
16. Bigliardi PL, Stammer H, Jost G, et al. Treatment of pruritus with topically applied opiate receptor antagonist. J Am Acad Dermatol 2007; 56(6):979-988. (Pubitemid 46720216)